Journal article

The relationship between coping and subclinical psychotic experiences in adolescents from the general population - a longitudinal study

A Lin, JTW Wigman, B Nelson, WAM Vollebergh, J van Os, G Baksheev, J Ryan, QAW Raaijmakers, A Thompson, AR Yung

PSYCHOLOGICAL MEDICINE | CAMBRIDGE UNIV PRESS | Published : 2011

Abstract

BACKGROUND: Subclinical psychotic experiences during adolescence may represent liability for developing psychotic disorder. Both coping style and the degree of persistence of psychotic experiences may play a role in the progression to clinical psychotic disorder, but little is known about the causal relationship between the two. METHOD: Path modelling was used to examine longitudinal relationships between subclinical positive psychotic experiences and three styles of coping (task-, emotion- and avoidance-oriented) in an adolescent general population sample (n=813) assessed three times in 3 years. Distinct developmental trajectories of psychotic experiences, identified with growth mixture mod..

View full abstract

Grants

Awarded by National Health and Medical Research Council (NHMRC)


Funding Acknowledgements

The current collaboration was supported by a grant to J.T.W.W. from the Dutch 'Stichting Koningsheide' and a National Health and Medical Research Council (NHMRC) program grant (no. 566529). The study was part funded by a National Alliance for Research on Schizophrenia and Depression (NARSAD) independent investigator award to A.R.Y. and an NHMRC program grant (no. 350241). B.N. is supported by a Ronald Phillip Griffith fellowship and an NARSAD young investigator award. A.R.Y. is supported by an NHMRC senior research fellowship and an NHMRC program grant (no. 566529). No funding source played any role in the collection, analysis, interpretation or publication of data.J.v.O. is/has been an unrestricted research grant holder with, or has received financial compensation as an independent symposium speaker from Eli Lilly, BMS, Lundbeck, Organon, Janssen-Cilag, GSK, AstraZeneca, Pfizer and Servier, companies that have an interest in the treatment of psychosis. A.R.Y. has received travel support and honoraria from Eli Lilly, BMS, Janssen-Cilag and AstraZeneca.